How to optimize the treatment strategy for patients with EGFR-mutant stage IA lung adenocarcinoma: an international multidisciplinary team

Affiliations

• ¹ The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, Guangzhou 510230, China.
• ² Department of Cardiothoracic Surgery, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai 318000, China.
• ³ Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, USA.
• ⁴ Medical Oncology Department, Istituto Toscano Tumori, Ospedale Civile-Livorno, Italy.
• ⁵ Department of Thoracic Medicine, The Prince Charles Hospital; Professor, School of Medicine, The University of Queensland, Brisbane, Australia.
• ⁶ Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Badalona, Barcelona, Spain.
• ⁷ Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
• ⁸ Department of Medicine and Surgery, Thoracic Surgery, University Hospital of Parma, Parma, Italy.
• ⁹ Department of Medical Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China.